Sintilimab versus docetaxel as second‐line treatment in advanced or metastatic squamous non‐small‐cell lung cancer: an open‐label, randomized controlled phase 3 trial (ORIENT‐3)
Yuankai Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Luyao Sun(Innovent), Wenwei Hu(Rutgers, The State University of New Jersey), Caicun Zhou(Tongji University), Puyuan Xing(Chinese Academy of Medical Sciences & Peking Union Medical College), Ying Yuan(Zhejiang Cancer Hospital), Yi Hu(Union Hospital), Gang Wu(University of Science and Technology of China), Sanyuan Sun, Yanqiu Zhao(Henan Cancer Hospital), Airong Wang(Fujian Agriculture and Forestry University), Jianying Zhou(First Affiliated Hospital Zhejiang University), Ying Cheng(Jilin Province Tumor Hospital), Tao Sun(Wuhan University), Yongqian Shu(Jiangsu Province Hospital), Jindong Shi(Fudan University), Qisen Guo(Shandong Tumor Hospital), Lin Wu(Materials Systems (United States)), Wěi Li(Shougang (China)), Lijun Wang(Beijing Tsinghua Chang Gung Hospital), Yang Zhang(Guangdong Testing Institute for Product Quality Supervision), Feng Ye(First Affiliated Hospital of Xiamen University), Yuan Chen(China General Nuclear Power Corporation (China)), Yong Song(Nanjing General Hospital of Nanjing Military Command), Changli Wang(Tianjin Medical University Cancer Institute and Hospital), Jianan Huang(Soochow University), Jifeng Feng(Jiangsu Cancer Hospital), Zhendong Wu(Nantong University), Zhendong Chen(University of Cologne), Yi Zhang(Roche (China)), Xinmin Yu(Zhejiang Cancer Hospital), Hongrui Niu(First Affiliated Hospital of Xinxiang Medical University), Jianhua Shi(Linyi People's Hospital), Guangyu An(Capital Medical University), Shucai Zhang(Northeastern University), Mengzhao Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Bo Peng(Tsinghua University), Ziping Wang(University of Science and Technology of China), Yanqi Wang(Target (United States)), Yong Fang(Tongji Hospital), Xingya Li(Zhengzhou University), Junye Wang(Sun Yat-sen University), Yunpeng Liu(Shenyang Institute of Automation), Christoph Mancao(Roche (Switzerland)), Yan Wang(National Institute of Biological Sciences, Beijing), Jiya Sun(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cited by 60
Related Papers
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
HIF-1α pathway: role, regulation and intervention for cancer therapy
|Acta Pharmaceutica Sinica B|2015|1.9k